Jean-Pascal Machiels
Overview
Explore the profile of Jean-Pascal Machiels including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
150
Citations
5401
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beyaert S, Loriot A, Machiels J, Schmitz S
Int J Mol Sci
. 2025 Mar;
26(5).
PMID: 40076457
Afatinib-induced tumor and microenvironment modifications in head and neck squamous cell carcinoma were evaluated by spatial transcriptomics in surgical specimens and RNA-sequencing in tumor biopsies of patients included in the...
2.
Giannatempo P, Machiels J, Sassa N, Arranz J, Fujii Y, Su W, et al.
Clin Genitourin Cancer
. 2025 Mar;
23(2):102273.
PMID: 40037029
Introduction: A post hoc analysis of efficacy and safety outcomes with pembrolizumab monotherapy was conducted in patients with advanced or metastatic urothelial carcinoma (UC) with pure transitional cell carcinoma (TCC)...
3.
Gambardella V, Ong M, Rodriguez-Ruiz M, Machiels J, Sanmamed M, Galvao V, et al.
Cancer Res Commun
. 2025 Feb;
5(3):422-432.
PMID: 39983024
Purpose: Therapeutic depletion of immunosuppressive regulatory T cells (Treg) may overcome resistance to cancer immunotherapies. RG6292 is an anti-CD25 antibody that preferentially depletes Tregs while preserving effector T-cell functions in...
4.
Van den Bossche V, Vignau J, Vigneron E, Rizzi I, Zaryouh H, Wouters A, et al.
Nat Commun
. 2025 Jan;
16(1):1237.
PMID: 39890801
Anti-epidermal growth factor receptor (EGFR) therapy (cetuximab) shows a limited clinical benefit for patients with locally advanced or recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), due to the frequent...
5.
Singer S, Hammerlid E, Tomaszewska I, Amdal C, Herlofson B, Santos M, et al.
Eur J Cancer
. 2024 Oct;
212:115062.
PMID: 39405647
Introduction: Minimal important change estimates (MIC) are useful for interpreting results of clinical research with quality of life (QoL) as an endpoint. For the European Organisation for Research and Treatment...
6.
Hamilton E, Galsky M, Ochsenreither S, Del Conte G, Martin M, De Miguel M, et al.
Clin Cancer Res
. 2024 Oct;
30(24):5548-5558.
PMID: 39405343
Purpose: This multicenter phase Ib study investigated trastuzumab deruxtecan (T-DXd) plus nivolumab in patients with HER2-expressing metastatic breast cancer (mBC) and metastatic urothelial cancer (mUC). Patients And Methods: Part 1...
7.
Beyaert S, Borys A, Baldin P, Dahou H, Magremanne M, Mahy P, et al.
Oral Oncol
. 2024 May;
154:106869.
PMID: 38820890
Objectives: Primary objective was to evaluate the correlation between immune marker expression in baseline tumor biopsies and their respective surgical specimens in squamous cell carcinoma of the oral cavity (OCSCC)....
8.
Enuset A, Duck L, Petre C, Machiels J, Goffin F
Front Oncol
. 2024 May;
14:1391408.
PMID: 38803539
Gestational trophoblastic neoplasia (GTN) is extremely rare, but has a very good prognosis, with a cure rate close to 100%, for low-risk diseases. This article describes the case of a...
9.
Machiels J, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, et al.
Lancet Oncol
. 2024 Apr;
25(5):572-587.
PMID: 38561010
Background: Despite multimodal therapy, 5-year overall survival for locally advanced head and neck squamous cell carcinoma (HNSCC) is about 50%. We assessed the addition of pembrolizumab to concurrent chemoradiotherapy for...
10.
Seiwert T, Wildsmith S, Fayette J, Harrington K, Gillison M, Ahn M, et al.
Cancer Immunol Immunother
. 2024 Mar;
73(4):70.
PMID: 38430375
Background: Selective biomarkers may improve outcomes in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitor therapy. We investigated three independent...